Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal adenocarcinoma: Early results from Big Ten Cancer Research Consortium study.
Hirva Mamdani(Wayne State University), Shadia I. Jalal(Indiana University Health), Bryan J. Schneider(Georgetown University), Thomas J. Birdas(Indiana University – Purdue University Indianapolis), Ahran Lee(Korea National Institute of Health), Laith Abushahin(The Ohio State University), Susan M. Perkins(Indiana University School of Medicine), Kenneth A. Kesler(Indiana University – Purdue University Indianapolis), Heather Burney(Indiana University – Purdue University Indianapolis)
Cited by 0
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2020|484
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
|Journal of Thoracic Oncology|2019|437
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|416